Exalenz Bioscience Ltd. announced that the China Food and Drug Administration (CFDA) has given Exalenz authorization to begin marketing and selling its BreathID® Hp Lab System for detection of H. pylori bacteria. The BreathID® Hp Lab System offers laboratories and hospitals several key benefits compared with other H. pylori tests, including: A non-invasive, non-radioactive approach to detecting H. pylori and confirming eradication after treatment; Requires only 15 minutes of a patient's time and only one hour fasting; Sample processing allows up to 30 tests to be processed each hour; Unsurpassed accuracy compared with other breath-based tests, with 100% sensitivity and 98% specificity; and System is fully automated and integrated into the hospital information management system eliminating the need for manual data entry and potential errors. Exalenz is currently establishing sales channels and distribution infrastructure, and expects to commence sales of the BreathID® Hp Lab System in China in the fourth quarter of 2019.